Exact Sciences tops expectations again; stock up sharply
October 31, 2018 at 11:03 AM EDT
Exact Sciences (Nasdaq: EXAS), the Middleton-based developer of the noninvasive Cologuard stool DNA-based colorectal cancer test, reported after markets closed Tuesday that test volume was 241,000 for the quarter, an increase of 49 percent.
